Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course

A 33-year-old G4P0 white female presented for a pregnancy ultrasound at 9 weeks gestation and was found to have a complete hydatidiform mole coexisting with a live twin fetus (CHTF). The β-hCG level was 600,000 mIU/ml and the chest X ray was negative. The pregnancy was uneventfully terminated by suc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 1997-07, Vol.66 (1), p.156-159
Hauptverfasser:	Hurteau, J.A., Roth, L.M., Schilder, J.M., Sumners, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics, Antineoplastic - therapeutic use Antimetabolites, Antineoplastic - therapeutic use Biological and medical sciences Dactinomycin - therapeutic use Diseases of mother, fetus and pregnancy Female Gynecology. Andrology. Obstetrics Humans Hydatidiform Mole - drug therapy Hydatidiform Mole - pathology Medical sciences Methotrexate - therapeutic use Pregnancy Pregnancy, Multiple Pregnancy. Fetus. Placenta Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	159
container_issue	1
container_start_page	156
container_title	Gynecologic oncology
container_volume	66
creator	Hurteau, J.A. Roth, L.M. Schilder, J.M. Sumners, J.
description	A 33-year-old G4P0 white female presented for a pregnancy ultrasound at 9 weeks gestation and was found to have a complete hydatidiform mole coexisting with a live twin fetus (CHTF). The β-hCG level was 600,000 mIU/ml and the chest X ray was negative. The pregnancy was uneventfully terminated by suction curettage and oral contraceptives were prescribed. The initial β-hCG declined appropriately; however, it subsequently rose. The metastatic workup was negative and the patient was treated with weekly intramuscular methotrexate at 30 mg/m2. The hCG levels declined appropriately and then plateaued. Salvage chemotherapy with intravenous actinomycin D at 1.25 mg/m2every 14 days was started. The hCG level normalized after 3 cycles and the patient was free of disease at 1 year follow-up.
doi_str_mv	10.1006/gyno.1997.4728
format	Article
fullrecord	<record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_gyno_1997_4728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825897947284</els_id><sourcerecordid>S0090825897947284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-c4367a3a74c7871a1e12d2fc989a359d2d153993b00a68818bbc29cb98e6e2153</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EKqWwsiF5YE3wRxLbbCiiFKkVS5ktx7kUo3xUdtrSf0-iVmxMN7zPe7p7ELqnJKaEZE-bY9vFVCkRJ4LJCzSlRKVRJlN1iaaEKBJJlsprdBPCNyGEE8omaKIYTxSXU7TKu2ZbQw94cSxN70pXdb7Bq64GnHfw40Lv2g0-uP4LG7w-uBYv3R7wHPpdeMZ57VpnTT2wOx_gFl1Vpg5wd54z9Dl_XeeLaPnx9p6_LCPLlegjm_BMGG5EYoUU1FCgrGSVVVIZnqqSlTTlSvGCEJNJSWVRWKZsoSRkwIZshuLTXuu7EDxUeutdY_xRU6JHLXrUokctetQyFB5Ohe2uaKD8w88ehvzxnJswvFN501oX_jAm0pRINmDyhMHw3N6B18E6aC2UzoPtddm5_y74BQlOfZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Hurteau, J.A. ; Roth, L.M. ; Schilder, J.M. ; Sumners, J.</creator><creatorcontrib>Hurteau, J.A. ; Roth, L.M. ; Schilder, J.M. ; Sumners, J.</creatorcontrib><description>A 33-year-old G4P0 white female presented for a pregnancy ultrasound at 9 weeks gestation and was found to have a complete hydatidiform mole coexisting with a live twin fetus (CHTF). The β-hCG level was 600,000 mIU/ml and the chest X ray was negative. The pregnancy was uneventfully terminated by suction curettage and oral contraceptives were prescribed. The initial β-hCG declined appropriately; however, it subsequently rose. The metastatic workup was negative and the patient was treated with weekly intramuscular methotrexate at 30 mg/m2. The hCG levels declined appropriately and then plateaued. Salvage chemotherapy with intravenous actinomycin D at 1.25 mg/m2every 14 days was started. The hCG level normalized after 3 cycles and the patient was free of disease at 1 year follow-up.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1997.4728</identifier><identifier>PMID: 9234938</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adult ; Antibiotics, Antineoplastic - therapeutic use ; Antimetabolites, Antineoplastic - therapeutic use ; Biological and medical sciences ; Dactinomycin - therapeutic use ; Diseases of mother, fetus and pregnancy ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Hydatidiform Mole - drug therapy ; Hydatidiform Mole - pathology ; Medical sciences ; Methotrexate - therapeutic use ; Pregnancy ; Pregnancy, Multiple ; Pregnancy. Fetus. Placenta ; Uterine Neoplasms - drug therapy ; Uterine Neoplasms - pathology</subject><ispartof>Gynecologic oncology, 1997-07, Vol.66 (1), p.156-159</ispartof><rights>1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-c4367a3a74c7871a1e12d2fc989a359d2d153993b00a68818bbc29cb98e6e2153</citedby><cites>FETCH-LOGICAL-c397t-c4367a3a74c7871a1e12d2fc989a359d2d153993b00a68818bbc29cb98e6e2153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/gyno.1997.4728$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2755082$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9234938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurteau, J.A.</creatorcontrib><creatorcontrib>Roth, L.M.</creatorcontrib><creatorcontrib>Schilder, J.M.</creatorcontrib><creatorcontrib>Sumners, J.</creatorcontrib><title>Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>A 33-year-old G4P0 white female presented for a pregnancy ultrasound at 9 weeks gestation and was found to have a complete hydatidiform mole coexisting with a live twin fetus (CHTF). The β-hCG level was 600,000 mIU/ml and the chest X ray was negative. The pregnancy was uneventfully terminated by suction curettage and oral contraceptives were prescribed. The initial β-hCG declined appropriately; however, it subsequently rose. The metastatic workup was negative and the patient was treated with weekly intramuscular methotrexate at 30 mg/m2. The hCG levels declined appropriately and then plateaued. Salvage chemotherapy with intravenous actinomycin D at 1.25 mg/m2every 14 days was started. The hCG level normalized after 3 cycles and the patient was free of disease at 1 year follow-up.</description><subject>Adult</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dactinomycin - therapeutic use</subject><subject>Diseases of mother, fetus and pregnancy</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Hydatidiform Mole - drug therapy</subject><subject>Hydatidiform Mole - pathology</subject><subject>Medical sciences</subject><subject>Methotrexate - therapeutic use</subject><subject>Pregnancy</subject><subject>Pregnancy, Multiple</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>Uterine Neoplasms - drug therapy</subject><subject>Uterine Neoplasms - pathology</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EKqWwsiF5YE3wRxLbbCiiFKkVS5ktx7kUo3xUdtrSf0-iVmxMN7zPe7p7ELqnJKaEZE-bY9vFVCkRJ4LJCzSlRKVRJlN1iaaEKBJJlsprdBPCNyGEE8omaKIYTxSXU7TKu2ZbQw94cSxN70pXdb7Bq64GnHfw40Lv2g0-uP4LG7w-uBYv3R7wHPpdeMZ57VpnTT2wOx_gFl1Vpg5wd54z9Dl_XeeLaPnx9p6_LCPLlegjm_BMGG5EYoUU1FCgrGSVVVIZnqqSlTTlSvGCEJNJSWVRWKZsoSRkwIZshuLTXuu7EDxUeutdY_xRU6JHLXrUokctetQyFB5Ohe2uaKD8w88ehvzxnJswvFN501oX_jAm0pRINmDyhMHw3N6B18E6aC2UzoPtddm5_y74BQlOfZs</recordid><startdate>19970701</startdate><enddate>19970701</enddate><creator>Hurteau, J.A.</creator><creator>Roth, L.M.</creator><creator>Schilder, J.M.</creator><creator>Sumners, J.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19970701</creationdate><title>Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course</title><author>Hurteau, J.A. ; Roth, L.M. ; Schilder, J.M. ; Sumners, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-c4367a3a74c7871a1e12d2fc989a359d2d153993b00a68818bbc29cb98e6e2153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dactinomycin - therapeutic use</topic><topic>Diseases of mother, fetus and pregnancy</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Hydatidiform Mole - drug therapy</topic><topic>Hydatidiform Mole - pathology</topic><topic>Medical sciences</topic><topic>Methotrexate - therapeutic use</topic><topic>Pregnancy</topic><topic>Pregnancy, Multiple</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>Uterine Neoplasms - drug therapy</topic><topic>Uterine Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurteau, J.A.</creatorcontrib><creatorcontrib>Roth, L.M.</creatorcontrib><creatorcontrib>Schilder, J.M.</creatorcontrib><creatorcontrib>Sumners, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurteau, J.A.</au><au>Roth, L.M.</au><au>Schilder, J.M.</au><au>Sumners, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1997-07-01</date><risdate>1997</risdate><volume>66</volume><issue>1</issue><spage>156</spage><epage>159</epage><pages>156-159</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>A 33-year-old G4P0 white female presented for a pregnancy ultrasound at 9 weeks gestation and was found to have a complete hydatidiform mole coexisting with a live twin fetus (CHTF). The β-hCG level was 600,000 mIU/ml and the chest X ray was negative. The pregnancy was uneventfully terminated by suction curettage and oral contraceptives were prescribed. The initial β-hCG declined appropriately; however, it subsequently rose. The metastatic workup was negative and the patient was treated with weekly intramuscular methotrexate at 30 mg/m2. The hCG levels declined appropriately and then plateaued. Salvage chemotherapy with intravenous actinomycin D at 1.25 mg/m2every 14 days was started. The hCG level normalized after 3 cycles and the patient was free of disease at 1 year follow-up.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>9234938</pmid><doi>10.1006/gyno.1997.4728</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0090-8258
ispartof	Gynecologic oncology, 1997-07, Vol.66 (1), p.156-159
issn	0090-8258 1095-6859
language	eng
recordid	cdi_crossref_primary_10_1006_gyno_1997_4728
source	MEDLINE; Access via ScienceDirect (Elsevier)
subjects	Adult Antibiotics, Antineoplastic - therapeutic use Antimetabolites, Antineoplastic - therapeutic use Biological and medical sciences Dactinomycin - therapeutic use Diseases of mother, fetus and pregnancy Female Gynecology. Andrology. Obstetrics Humans Hydatidiform Mole - drug therapy Hydatidiform Mole - pathology Medical sciences Methotrexate - therapeutic use Pregnancy Pregnancy, Multiple Pregnancy. Fetus. Placenta Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology
title	Complete Hydatidiform Mole Coexisting with a Twin Live Fetus: Clinical Course
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T21%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20Hydatidiform%20Mole%20Coexisting%20with%20a%20Twin%20Live%20Fetus:%20Clinical%20Course&rft.jtitle=Gynecologic%20oncology&rft.au=Hurteau,%20J.A.&rft.date=1997-07-01&rft.volume=66&rft.issue=1&rft.spage=156&rft.epage=159&rft.pages=156-159&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1997.4728&rft_dat=%3Celsevier_cross%3ES0090825897947284%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9234938&rft_els_id=S0090825897947284&rfr_iscdi=true